Ozempic and Mounjaro
- Emre Ozturk
- Sep 20
- 3 min read
In recent years, the increasing number of patients with obesity and type 2 diabetes has brought forward the need for more effective pharmacological treatments. New-generation drugs in this field stand out with their potential not only to improve glycemic control but also to provide significant weight loss. Semaglutide (Ozempic) and tirzepatide (Mounjaro) are leading representatives of this class and are now considered the beginning of a new era in the treatment of obesity as well as in the management of diabetes.
Semaglutide (Ozempic)
Semaglutide, known commercially as Ozempic, mimics the action of the GLP-1 hormone naturally produced in the human body. By binding to GLP-1 receptors, Ozempic increases insulin secretion from the pancreas, suppresses glucagon release, and thereby lowers blood sugar levels. In addition, by slowing gastric emptying and acting on the appetite center in the brain, it enhances the feeling of satiety and reduces calorie intake.
